Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545080 | 0.92 | KMT2A (0.46) | MAPTTP53KMT2AGAAMAPK1 | |
| SCHEMBL17545362 | 0.92 | KMT2A (0.46) | MAPTTP53KMT2AGAAMAPK1 | |
| SCHEMBL19219756 | 0.88 | ACLY (0.42) | MAPTTP53KMT2AGAAMAPK1 | |
| SCHEMBL19222362 | 0.80 | ACLY (0.50) | MAPTKMT2AGAAMAPK1LMNA | |
| SCHEMBL17545350 | 0.80 | ACLY (0.50) | MAPTKMT2AGAAMAPK1LMNA | |
| SCHEMBL17545309 | 0.80 | ACLY (0.50) | MAPTKMT2AGAAMAPK1LMNA | |
| SCHEMBL19219753 | 0.77 | POLB (0.42) | TP53GAALMNASMN1; SMN2POLB | |
| SCHEMBL19219765 | 0.73 | LMNA (0.40) | MAPTKMT2ALMNASMN1; SMN2TRIM24 | |
| SCHEMBL17545216 | 0.72 | POLB (0.54) | MAPTTP53KMT2AGAAMAPK1 | |
| SCHEMBL19222298 | 0.71 | POLB (0.47) | MAPTTP53KMT2AGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | MAPT 2069/4885TP53 3211/4885KMT2A 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.